Beijing Furen Ruihui Biomedical Research Institute Co., Ltd. (北京辅仁瑞辉生物医药研究院有限公司)

概览

关联

2

项与北京辅仁瑞辉生物医药研究院有限公司相关的临床试验

NCT03747653

/ Unknown statusN/A

A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A.
Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in patients with hemophilia A.

开始日期2019-03-08

申办/合作机构

开封制药（集团）有限公司

[+1]

ChiCTR1800019483

/ Completed临床1期IIT

A Phase I, Multicentre, Open-Label, Self-control Study for Evaluation of the Pharmacokinetics, Safety and Tolerability of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection in Adolescent and Adult Patients With Hemophilia A

开始日期2018-11-02

申办/合作机构

北京辅仁瑞辉生物医药研究院有限公司

[+1]

100 项与北京辅仁瑞辉生物医药研究院有限公司相关的临床结果

登录后查看更多信息

0 项与北京辅仁瑞辉生物医药研究院有限公司相关的专利（医药）

登录后查看更多信息

100 项与北京辅仁瑞辉生物医药研究院有限公司相关的药物交易

登录后查看更多信息

100 项与北京辅仁瑞辉生物医药研究院有限公司相关的转化医学

登录后查看更多信息